Der Band zeichnet die oft spektakulären Erfolgs- oder Misserfolgsgeschichten neuartiger pharmazeutischer Wirkstoffe nach und nimmt den Leser dabei mit auf die Reise von den ersten Anfängen der Heilkunde bis zum Milliardengeschäft der modernen Pharmaindustrie. Sachkundig geschrieben, reich illustriert, anregend: Eine unterhaltsame Lektüre!
Der Band zeichnet die oft spektakulären Erfolgs- oder Misserfolgsgeschichten neuartiger pharmazeutischer Wirkstoffe nach und nimmt den Leser dabei mit auf die Reise von den ersten Anfängen der Heilkunde bis zum Milliardengeschäft der modernen Pharmaindustrie. Sachkundig geschrieben, reich illustriert, anregend: Eine unterhaltsame Lektüre!Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Die Herstellerinformationen sind derzeit nicht verfügbar.
Autorenporträt
Enrique Ravina studied pharmacy at the University of Santiago de Compostela, Spain, where he obtained his PhD in 1969 and was appointed Professor of Organic Chemistry in 1975. Since 1981 he is Professor of Medicinal/Pharmaceutical Chemistry at the same University. He is a member of the Spanish Royal Academy of Pharmacy, a founding member of the Spanish Society of Medicinal Chemistry and a member of the American Chemical Society. Professor Ravina has over 120 publications to his name in the field of chemistry of drugs, especially in the area of antipsychotic and cardiovascular potential drugs, including a book, book chapters, as well as a co-inventor of the world patent "6-phenyldihydropyrrolopyrimidinedione derivatives".
Inhaltsangabe
Foreword Preface and Acknowledgment
EVOLUTION OF DRUG DISCOVERY Antiquity Great Periods of Drug Discovery Vaccines
THE FIRST SYNTHETIC DRUGS AND THE BIRTH OF CHEMOTHERAPY Aspirin, Phenacetin, and Paracetamol Discovery of Pyrazolones Cocaine and Local Anesthetics Barbiturates and Related Compounds Fathers of Chemotherapy
FROM CASUAL OBSERVATIONS TO SYSTEMATIC SEARCH From Antihistamines to Antipsychotics and Antidepressants: The Origins of Psychopharmacology Benzodiazepines Structural Variations on Sulfanilamide Azoles as a Source of Antibacterials, Antifungals, and Antihelmintics The Long Fight Against Cancer Sildenafil - The First Inhibitor of Rectile Dysfunction
NATURE AS A SOURCE OF DRUGS: DRUGS FROM NATURAL PRODUCTS Plant Sources: Derivatives and Related Drugs (Selected Examples) Animal Sources: Derivatives and Related Drugs Drugs from Microbiological Sources Drugs from Marine Origin: The Contribution of the Sea to the Therapeutic Arsenal
RATIONALIZING THE DRUG DISCOVERY PROCESS Early Rational Drug Discovery Approaches: L-Dopa and L-Alpha-Methyldopa Receptor-Based Drug Discovery Antimetabolites in the Fight Against Bacteria, Viruses, and Cancer Cyclooxygenase(COX) Inhibitors
STRUCTURE-BASED DRUG DISCOVERY Searching for the Ideal Antihypertensive Agent: Renin-Angiotensin-Aldosterone System (RAAS) HIV Protease Inhibitors Drugs Effective Against the Influenza Virus (the Flu) Fight Against Cancer New Avenues for the Development of Antidiabetic Agents. Dipeptidyl-Peptidase-IV Inhibitors: Sitagliptin and Vildaglptin
BIOPHARMACEUTICALS Monoclonal Antibodies (MAbs) Recombinant DNA Technology (Genetic Engineering) Some Recombinant Protein Drugs Protein-Polyethyleneglycol (PEG) Conjugates (Protein PEGylation)
DRUG DISCOVERY IN THE POSTGENOMIC ERA: CONCLUDING REMARKS Chemical/Genomic Strategy Summary
EVOLUTION OF DRUG DISCOVERY Antiquity Great Periods of Drug Discovery Vaccines
THE FIRST SYNTHETIC DRUGS AND THE BIRTH OF CHEMOTHERAPY Aspirin, Phenacetin, and Paracetamol Discovery of Pyrazolones Cocaine and Local Anesthetics Barbiturates and Related Compounds Fathers of Chemotherapy
FROM CASUAL OBSERVATIONS TO SYSTEMATIC SEARCH From Antihistamines to Antipsychotics and Antidepressants: The Origins of Psychopharmacology Benzodiazepines Structural Variations on Sulfanilamide Azoles as a Source of Antibacterials, Antifungals, and Antihelmintics The Long Fight Against Cancer Sildenafil - The First Inhibitor of Rectile Dysfunction
NATURE AS A SOURCE OF DRUGS: DRUGS FROM NATURAL PRODUCTS Plant Sources: Derivatives and Related Drugs (Selected Examples) Animal Sources: Derivatives and Related Drugs Drugs from Microbiological Sources Drugs from Marine Origin: The Contribution of the Sea to the Therapeutic Arsenal
RATIONALIZING THE DRUG DISCOVERY PROCESS Early Rational Drug Discovery Approaches: L-Dopa and L-Alpha-Methyldopa Receptor-Based Drug Discovery Antimetabolites in the Fight Against Bacteria, Viruses, and Cancer Cyclooxygenase(COX) Inhibitors
STRUCTURE-BASED DRUG DISCOVERY Searching for the Ideal Antihypertensive Agent: Renin-Angiotensin-Aldosterone System (RAAS) HIV Protease Inhibitors Drugs Effective Against the Influenza Virus (the Flu) Fight Against Cancer New Avenues for the Development of Antidiabetic Agents. Dipeptidyl-Peptidase-IV Inhibitors: Sitagliptin and Vildaglptin
BIOPHARMACEUTICALS Monoclonal Antibodies (MAbs) Recombinant DNA Technology (Genetic Engineering) Some Recombinant Protein Drugs Protein-Polyethyleneglycol (PEG) Conjugates (Protein PEGylation)
DRUG DISCOVERY IN THE POSTGENOMIC ERA: CONCLUDING REMARKS Chemical/Genomic Strategy Summary
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Internetauftritt der buecher.de internetstores GmbH
Geschäftsführung: Monica Sawhney | Roland Kölbl | Günter Hilger
Sitz der Gesellschaft: Batheyer Straße 115 - 117, 58099 Hagen
Postanschrift: Bürgermeister-Wegele-Str. 12, 86167 Augsburg
Amtsgericht Hagen HRB 13257
Steuernummer: 321/5800/1497
USt-IdNr: DE450055826
